Repeated need for tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · patients with psychosis‐induced aggression or agitation
2 findings from 1 review
Adverse effect: any serious, specific ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · psychosis‐induced aggression or agitation
HALOPERIDOL may leads to higher adverse effects compared with OTHER ANTIPSYCHOTICS: g. QUETIAPINE (low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in no significant clinical response: short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · patients with schizophrenia
1 finding from 1 review